A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes

被引:348
作者
Antoniou, AC
Pharoah, PDP
McMullan, G
Day, NE
Stratton, MR
Peto, J
Ponder, BJ
Easton, DF
机构
[1] Univ Cambridge, Strangeways Res Lab, Inst Publ Hlth, CRC Genet Epidemiol Unit, Cambridge CB1 8RN, England
[2] Univ Cambridge, CRC Human Canc Genet Res Grp, Cambridge CB1 8RN, England
[3] Univ Cambridge, Cavendish Lab, High Performance Comp Facil, Cambridge CB1 8RN, England
[4] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England
[5] Inst Canc Res, Surrey, England
关键词
segregation analysis; BRCA3; Polygenes; high-risk families; population studies;
D O I
10.1038/sj.bjc.6600008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In computing the probability that a woman is a BRCA1 or BRCA2 carrier for genetic counselling purposes, it is important to allow for the fact that other breast cancer susceptibility genes may exist. We used data from both a population based series of breast cancer cases and high risk families in the UK, with information on BRCA1 and BRCA2 mutation status, to invest gate the genetic models that can best explain familial breast cancer outside BRCA1 and BRCA2 families. We also evaluated the evidence for risk modifiers in BRCA1 and BRCA2 carriers, We estimated the simultaneous effects of BRCA1. BRCA2, a third hypothetical gene 'BRCA3', and a polygenic effect using segregation analysis. The hypergeometric polygenic model was used to approximate polygenic inheritance and the effect of risk modifiers, BRCA1 and BRCA2 could not explain all the observed familial clustering. The best fitting model for the residual familial breast cancer was the polygenic, although a model with a single recessive allele produced a similar fit. There was also significant evidence for a modifying effect of other genes on the risks of breast cancer in BRCA1 and BRCA2 mutation carriers. Under this model, the frequency of BRCA1 was estimated to be 0.051% (95% CI: 0.021-0.125%) and of BRCA2 0.068% (95% CI: 0.033-0.141%). The breast cancer risk by age 70 years, based on the average incidence over all modifiers was estimated to be 35.3% for BRCA1 and 50.3% for BRCA2. The corresponding ovarian cancer risks were 25.9% for BRCA1 and 9.1% for BRCA2. The Findings suggest that several common, low penetrance genes with multiplicative effects, on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer. The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families.
引用
收藏
页码:76 / 83
页数:8
相关论文
共 35 条
  • [21] GERM LINE P53 MUTATIONS IN A FAMILIAL SYNDROME OF BREAST-CANCER, SARCOMAS, AND OTHER NEOPLASMS
    MALKIN, D
    LI, FP
    STRONG, LC
    FRAUMENI, JF
    NELSON, CE
    KIM, DH
    KASSEL, J
    GRYKA, MA
    BISCHOFF, FZ
    TAINSKY, MA
    FRIEND, SH
    [J]. SCIENCE, 1990, 250 (4985) : 1233 - 1238
  • [22] Localization of the gene for Cowden disease to chromosome 10q22-23
    Nelen, MR
    Padberg, GW
    Peeters, EAJ
    Lin, AY
    vandenHelm, B
    Frants, RR
    Coulon, V
    Goldstein, AM
    vanReen, MMM
    Easton, DF
    Eeles, RA
    Hodgson, S
    Mulvihill, JJ
    Murday, VA
    Tucker, MA
    Mariman, ECM
    Starink, TM
    Ponder, BAJ
    Ropers, HH
    Kremer, H
    Longy, M
    Eng, C
    [J]. NATURE GENETICS, 1996, 13 (01) : 114 - 116
  • [23] Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries
    Olsen, JH
    Hahnemann, JM
    Borresen-Dale, AL
    Brondum-Nielsen, K
    Hammarström, L
    Kleinerman, R
    Käätriäinen, H
    Lönnqvist, T
    Sankila, R
    Seersholm, N
    Tretli, S
    Yuen, J
    Boice, JD
    Tucker, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (02): : 121 - 127
  • [24] Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
    Parmigiani, G
    Berry, DA
    Aguilar, O
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (01) : 145 - 158
  • [25] Pharoah PDP, 1997, INT J CANCER, V71, P800, DOI 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO
  • [26] 2-B
  • [27] Ponder BAJ, 2000, BRIT J CANCER, V83, P1301
  • [28] REBBECK T, 1999, CARCINOGENESIS, V40, P194
  • [29] Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat
    Rebbeck, TR
    Kantoff, PN
    Krithivas, K
    Neuhausen, S
    Blackwood, MA
    Godwin, AK
    Daly, MB
    Narod, SA
    Garber, JE
    Lynch, HT
    Weber, BL
    Brown, M
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (05) : 1371 - 1377
  • [30] Rebbeck TR, 1999, CANCER-AM CANCER SOC, V86, P2493, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2493::AID-CNCR6>3.0.CO